Related Experiment Video

Updated: Jan 3, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.5K

Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death

Xiaoou Xu1, Shizuka Eshima1, Shinichiro Kato1,2

  • 1Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama, Japan.

Molecular Cancer Therapeutics
|November 21, 2019
PubMed

Insights

Dinaciclib shows potent antimelanoma effects by inducing BAK-dependent apoptosis, offering a novel strategy to overcome resistance to BRAF inhibitors. Combining dinaciclib with BRAF/MEK inhibitors synergistically inhibits melanoma growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • BRAF oncogene mutations are frequent in melanoma.
  • BRAF and MEK inhibitors often fail to eradicate melanoma due to resistance.
  • Novel therapeutic strategies are required to enhance BRAF inhibition efficacy.

Purpose of the Study:

  • To investigate the antimelanoma effects of dinaciclib.
  • To explore the apoptotic mechanisms induced by dinaciclib and BRAF/MEK inhibitors.
  • To evaluate the synergistic potential of combining dinaciclib with BRAF/MEK inhibitors.

Main Methods:

  • In vitro and in vivo melanoma models.
  • Assessment of apoptosis induction via BAK- and BAX-dependent pathways.
  • Evaluation of drug combination efficacy.

Main Results:

  • Dinaciclib induces BAK-dependent apoptosis by reducing MCL1.
  • BRAF/MEK/CDK4/6 inhibitors induce BAX-dependent apoptosis.
  • Combination of dinaciclib with BRAF/MEK inhibitors shows synergistic inhibition of melanoma growth.

Conclusions:

  • Dinaciclib is a potent agent for melanoma treatment, inducing BAK-mediated apoptosis.
  • Dinaciclib acts as a complementary drug to BAX-dependent therapies.
  • Rational drug combinations targeting BAK or BAX pathways can improve melanoma treatment.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K